Better Therapeutics, Inc.
BTTX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $2 | $3 | $3 |
| G&A Expenses | $2 | $3 | $3 | $4 |
| SG&A Expenses | $4 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $1 | $2 | $2 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $7 | $9 | $8 |
| Operating Income | -$5 | -$7 | -$9 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$0 |
| Pre-Tax Income | -$6 | -$8 | -$9 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$8 | -$9 | -$9 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.24 | -0.39 | -0.37 |
| % Growth | 37.5% | 38.5% | -5.4% | – |
| EPS Diluted | -0.15 | -0.24 | -0.39 | -0.37 |
| Weighted Avg Shares Out | 38 | 31 | 24 | 24 |
| Weighted Avg Shares Out Dil | 38 | 31 | 24 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$5 | -$6 | -$8 | -$8 |
| % Margin | – | – | – | – |